Psychostimulants act on monoamine systems including the dopamine transporter (DAT), a key regulator of dopamine reuptake following synaptic release. While these compounds can enhance energy, cognition, and sociability, their clinical utility is often limited by their abuse potential and peripheral side effects. Research has traditionally focused more on their addictive properties rather than their therapeutic potential. However, certain psychostimulants, such as R-modafinil, enhance cognitive performance without inducing significant euphoria or addiction, making them promising lead candidates for clinical application. In this study, we hypothesized that R-modafinil analogs with extended residence time at DAT (i.e., slow koff) would enhance cognitive function more effectively. To test this, we evaluated a series of R-modafinil analogs using in vitro equilibrium and non-equilibrium measurements, in vivo fast-scan cyclic voltammetry, and highly translational cognitive assays in both healthy and scopolamine-treated rats modelling cognitive impairment. Our findings show that prolonging DAT occupancy improves dopamine signalling and leads to more robust enhancements in cognitive flexibility. Compounds with longer DAT resident time-such as S-MK-26 and (S,S)-CE-158-produced the strongest cognitive effects. These results highlight the importance of DAT binding kinetics in shaping the behavioural actions of psychostimulants and support the development of safer and more effective dopamine-based cognitive enhancers.
Background/Objectives: Metabolic stability is an important determinant of the pharmacokinetic properties of drug candidates, as metabolic instability may limit systemic exposure and lead to the formation of metabolites with distinct pharmacological properties. Here, we characterized the phase I metabolic stability and biotransformation pathways of five phenyl-substituted benzimidazole-based muscarinic acetylcholine receptor (mAChR) antagonists using an integrated in vitro and in silico approach. Methods: Metabolic stability, microsomal binding, and metabolite formation were investigated in human liver microsomes using liquid chromatography coupled to high-resolution and tandem mass spectrometry. GLORY, GLORYx, and FAME3R were used to rank possible sites of metabolism, while SwissADME was applied to estimate physicochemical and pharmacokinetic properties of the parent compounds and putative metabolites. Molecular docking was further used to explore potential effects of metabolic transformations on target interactions. Results: Compound 4 showed the most rapid metabolic turnover, whereas 1 displayed the highest intrinsic metabolic stability after correction for microsomal binding. Hydroxylation was the most frequently observed phase I transformation, with N-demethylation consistently detected across the series. Several putative metabolites were predicted to have properties consistent with P-glycoprotein (P-gp) substrate recognition and reduced brain penetration, whereas the parent compounds were not predicted to be P-gp substrates except for 4. Conclusions: The study defines major metabolic transformation pathways within this benzimidazole-based mAChR antagonist series and identifies metabolic liabilities that may be relevant to further compound optimization. The combined experimental and computational approach provides a framework for interpreting metabolic profiles and generating hypotheses for subsequent pharmacokinetic and structure activity investigations.